Project CBD

FEBRUARY 27, 2023

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.” It’s not a new idea.

THC 144

THC CBD Clinical Trials Sleep 144

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz, a clinical psychologist, led the development of the ORR as a postdoctoral research fellow at Johns Hopkins University. About Realm of Caring.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

JULY 18, 2023

This could foster a pool of experts well-versed in applying psychedelic-assisted therapy. Clinical Trials and Reporting The bill breaks new ground by allowing clinical trials to take place regardless of whether the tested substances fall under federal or military statutes.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

The Cannigma

FEBRUARY 2, 2021

Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.

Patients 107

Patients Clinical Trials Research and Development Treatment 107

CannaTech

SEPTEMBER 23, 2019

NICE develop evidence-based guidelines on a wide range of health-related topics, including integrating novel and emerging therapies. Last week NICE released the first draft of their evidence-based guidelines, concluding it could not recommend CBMPs for routine use because of high cost and a dearth of clinical trial evidence.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).

Clinical Trials 40

Clinical Trials Treatment Research and Development Media 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development 124

Research and Development Data THC Clinical Trials 124

Greencamp

FEBRUARY 2, 2019

These medications are combined in what’s known as HAART (highly active antiretroviral therapy). Even though these pharmaceuticals slow down the progression and lessen the quantity of the virus in a patient’s body, many sufferers experience severe pain from antiretroviral therapy. Cannabis as a palliative aid for HIV patients.

Marijuana 110

Marijuana Therapy Cannabinoids Patients 110

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

NOVEMBER 23, 2021

Crystalline psilocybin is used in COMP360, COMPASS’s synthesised psilocybin formulation being developed for psilocybin therapy in TRD. Patents enable us to continue to do the highest quality clinical research so we can work to bring therapies to patients who are suffering with serious mental health challenges and have few options.”

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JULY 6, 2021

Johnson, DSc, MD, MPhil, FRCPsych said, “I am pleased to join the Ehave Medical Advisory Board and look forward to working towards bringing psychedelic-assisted therapies to patients experiencing substance use issues. ” About Ehave, Inc. Ehave, Inc. Forward-Looking Statement Disclaimer.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 51

DEA Clinical Trials THC Research and Development 51

Cannabis Law Report

AUGUST 3, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Applied DNA is also the manufacturer of the EUA-authorized Linea™ COVID-19 Assay Kit. Food and Drug Administration (U.S.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

JULY 8, 2021

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids.

Research and Development 85

Research and Development Pets Cannabinoids Clinical Trials 85

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Food and Drug Administration (U.S.

Clinical Trials 76

Clinical Trials Therapy Research and Development Collective 76

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Building the Data Backend. Mental Health Challenges. Psychedelics could offer a better alternative for many patients. MedXtractor Corp.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

LifeCannMD

MAY 27, 2025

Sleep: What the Sleep Studies Reveal A groundbreaking 2020 study from the University of New Mexico analyzed sleep data from over 5,000 medical marijuana patients. After six months of microdosing marijuana (2mg THC + 2mg CBD twice daily), his pain went from an 8/10 to a 3/10, and he’s back to playing golf three times a week.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Medicinal cannabis has been so effective I don’t even think about other therapies,” Rocky said. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

The Cannigma

AUGUST 31, 2021

The researchers stated that these knowledge gaps must be addressed and that “clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”.

Education 105

Education Clinical Trials Medicine Policy 105

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52